Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
It was approved by the FDA in April 2026 as the first oral GLP-1 agonist that does not require absorption enhancers or food restrictions
To assess safety of sustained weight reduction with Vutiglabridin with Semaglutide combination, we conducted an 8-week study in normal rats using more than 3 times efficacious mouse doses, monitoring body weight, food intake, and safety parameters
Cycle length depends on the goal
In a phase 2 clinical trial targeting obese individuals without type 2 diabetes (T2D), retatrutide dosed at 1 to 12 mg resulted in up to 24.2% weight loss over a 48-week treatment period, compared to 2.1% in the placebo group, and demonstrated a dose-dependent effect
Heat stress-induced hepatotoxicity and its prevention by resveratrol in rats
